Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo Dragoni

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
International Journal of Molecular Sciences|April 3, 2021
Sofosbuvir Selects for Drug-Resistant Amino Acid Variants in the Zika Virus RNA-Dependent RNA-Polymerase Complex In VitroAdele Boccuto, Filippo Dragoni, Francesca Picarazzi, et al.
Viruses|July 27, 2022
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2Lia Fiaschi, Filippo Dragoni, Elisabetta Schiaroli, et al.
Cells|September 9, 2022
Cellular and Molecular Mechanisms of In Vivo and In Vitro SARS-CoV-2 Infection: A Lesson from Human SpermAlice Luddi, Francesca Paola Luongo, Filippo Dragoni, et al.
Vaccines|August 26, 2022
Long-Term Longitudinal Analysis of Neutralizing Antibody Response to Three Vaccine Doses in a Real-Life Setting of Previously SARS-CoV-2 Infected Healthcare Workers: A Model for Predicting Response to Further Vaccine DosesSaverio Giuseppe Parisi, Carlo Mengoli, Monica Basso, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 15, 2022
Dynamics of Total and Intact HIV-1 DNA in Virologically Suppressed Patients Switching to DTG-Based or ATV-Based Dual TherapyFilippo Dragoni, Barbara Rossetti, Francesca Lombardi, et al.
The Journal of General Virology|October 13, 2020
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and <i>ex vivo</i> CD4 T cellsIlaria Vicenti, Filippo Dragoni, Martina Monti, et al.
Biorxiv : the Preprint Server for Biology|June 22, 2026
Antigen Stimulation Reactivates HIV-1 Proviruses Despite Integration in Repressive ChromatinAngelica Camilo-Contreras, Filippo Dragoni, Hao Zhang, et al.
European Journal of Medicinal Chemistry|July 17, 2021
System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2Ilaria Vicenti, Maria Grazia Martina, Adele Boccuto, et al.
Scientific Reports|March 1, 2022
External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in ItalyIlaria Vicenti, Filippo Dragoni, Alessia Giannini, et al.
Immunity|November 29, 2024
Cognate antigen engagement induces HIV-1 expression in latently infected CD4<sup>+</sup> T cells from people on long-term antiretroviral therapyMilica Moskovljevic, Filippo Dragoni, Nathan L Board, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
International Journal of Molecular Sciences|April 3, 2021
Sofosbuvir Selects for Drug-Resistant Amino Acid Variants in the Zika Virus RNA-Dependent RNA-Polymerase Complex In VitroAdele Boccuto, Filippo Dragoni, Francesca Picarazzi, et al.
Viruses|July 27, 2022
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2Lia Fiaschi, Filippo Dragoni, Elisabetta Schiaroli, et al.
Cells|September 9, 2022
Cellular and Molecular Mechanisms of In Vivo and In Vitro SARS-CoV-2 Infection: A Lesson from Human SpermAlice Luddi, Francesca Paola Luongo, Filippo Dragoni, et al.
Vaccines|August 26, 2022
Long-Term Longitudinal Analysis of Neutralizing Antibody Response to Three Vaccine Doses in a Real-Life Setting of Previously SARS-CoV-2 Infected Healthcare Workers: A Model for Predicting Response to Further Vaccine DosesSaverio Giuseppe Parisi, Carlo Mengoli, Monica Basso, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 15, 2022
Dynamics of Total and Intact HIV-1 DNA in Virologically Suppressed Patients Switching to DTG-Based or ATV-Based Dual TherapyFilippo Dragoni, Barbara Rossetti, Francesca Lombardi, et al.
The Journal of General Virology|October 13, 2020
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and <i>ex vivo</i> CD4 T cellsIlaria Vicenti, Filippo Dragoni, Martina Monti, et al.
Biorxiv : the Preprint Server for Biology|June 22, 2026
Antigen Stimulation Reactivates HIV-1 Proviruses Despite Integration in Repressive ChromatinAngelica Camilo-Contreras, Filippo Dragoni, Hao Zhang, et al.
European Journal of Medicinal Chemistry|July 17, 2021
System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2Ilaria Vicenti, Maria Grazia Martina, Adele Boccuto, et al.
Scientific Reports|March 1, 2022
External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in ItalyIlaria Vicenti, Filippo Dragoni, Alessia Giannini, et al.
Immunity|November 29, 2024
Cognate antigen engagement induces HIV-1 expression in latently infected CD4<sup>+</sup> T cells from people on long-term antiretroviral therapyMilica Moskovljevic, Filippo Dragoni, Nathan L Board, et al.
Pageof 4